BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27067045)

  • 1. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
    Xavier C; Blykers A; Vaneycken I; D'Huyvetter M; Heemskerk J; Lahoutte T; Devoogdt N; Caveliers V
    Nucl Med Biol; 2016 Apr; 43(4):247-52. PubMed ID: 27067045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.
    Vaidyanathan G; McDougald D; Choi J; Koumarianou E; Weitzel D; Osada T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2016 Jun; 57(6):967-73. PubMed ID: 26912425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor.
    Miao Z; Ren G; Jiang L; Liu H; Webster JM; Zhang R; Namavari M; Gambhir SS; Syud F; Cheng Z
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1977-84. PubMed ID: 21761266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling.
    Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Lyerly HK; Zalutsky MR
    J Nucl Med; 2014 Apr; 55(4):650-6. PubMed ID: 24578241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorine-18 Labeling of the HER2-Targeting Single-Domain Antibody 2Rs15d Using a Residualizing Label and Preclinical Evaluation.
    Zhou Z; Vaidyanathan G; McDougald D; Kang CM; Balyasnikova I; Devoogdt N; Ta AN; McNaughton BR; Zalutsky MR
    Mol Imaging Biol; 2017 Dec; 19(6):867-877. PubMed ID: 28409338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments.
    Blykers A; Schoonooghe S; Xavier C; D'hoe K; Laoui D; D'Huyvetter M; Vaneycken I; Cleeren F; Bormans G; Heemskerk J; Raes G; De Baetselier P; Lahoutte T; Devoogdt N; Van Ginderachter JA; Caveliers V
    J Nucl Med; 2015 Aug; 56(8):1265-71. PubMed ID: 26069306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
    Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and radiopharmacological evaluation of a high-affinity and metabolically stabilized 18F-labeled bombesin analogue for molecular imaging of gastrin-releasing peptide receptor-expressing prostate cancer.
    Richter S; Wuest M; Krieger SS; Rogers BE; Friebe M; Bergmann R; Wuest F
    Nucl Med Biol; 2013 Nov; 40(8):1025-34. PubMed ID: 23969085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Labeling a TCO-functionalized single domain antibody fragment with
    Zhou Z; Zalutsky MR; Vaidyanathan G
    Bioorg Med Chem; 2020 Sep; 28(17):115634. PubMed ID: 32773089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three methods for 18F labeling of the HER2-binding affibody molecule Z(HER2:2891) including preclinical assessment.
    Glaser M; Iveson P; Hoppmann S; Indrevoll B; Wilson A; Arukwe J; Danikas A; Bhalla R; Hiscock D
    J Nucl Med; 2013 Nov; 54(11):1981-8. PubMed ID: 24115530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
    Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
    J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
    Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
    Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the first
    Honarvar H; Müller C; Cohrs S; Haller S; Westerlund K; Karlström AE; van der Meulen NP; Schibli R; Tolmachev V
    Nucl Med Biol; 2017 Feb; 45():15-21. PubMed ID: 27837664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative PET Imaging of Tissue Factor Expression Using 18F-Labeled Active Site-Inhibited Factor VII.
    Nielsen CH; Erlandsson M; Jeppesen TE; Jensen MM; Kristensen LK; Madsen J; Petersen LC; Kjaer A
    J Nucl Med; 2016 Jan; 57(1):89-95. PubMed ID: 26383146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an Anti-HER2 Nanobody Labeled with
    Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
    Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of [
    Ducharme M; Hall L; Eckenroad W; Cingoranelli SJ; Houson HA; Jaskowski L; Hunter C; Larimer BM; Lapi SE
    Mol Pharm; 2023 Sep; 20(9):4629-4639. PubMed ID: 37552575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.
    Wållberg H; Grafström J; Cheng Q; Lu L; Martinsson Ahlzén HS; Samén E; Thorell JO; Johansson K; Dunås F; Olofsson MH; Stone-Elander S; Arnér ES; Ståhl S
    J Nucl Med; 2012 Sep; 53(9):1446-53. PubMed ID: 22872744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.